Bispecific Antibody Therapeutics Market is Booming Worldwide with USD 900.29 Million During the Forecast Period 2029

Bispecific Antibody Therapeutics Market analysis report covers detailed value chain analysis of the market. The value chain analysis helps to analyze major upstream raw materials, major equipment's, manufacturing process, and downstream customer analysis and major distributor analysis are mentioned in the report along with all the drivers and restraints for the market. It presents a comparative detailed analysis of all regional and player segments, offering readers a better knowledge of the areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the market.

In 2018, approximately 4,285,033 new cancer cases were detected in China, according to Globocan's estimations. As a result, the increased global prevalence of cancer necessitates new therapeutic choices, driving up demand for bispecific antibodies. Bispecific antibodies (BsAbs) are antibodies that can bind two distinct antigens simultaneously (or different epitopes of the same antigen). BsAbs have mostly been used to reroute cytotoxic immune effector cells for improved tumor cell killing via antibody-dependent cell-mediated cytotoxicity (ADCC) and other cytotoxic processes mediated by effector cells.

Data Bridge Market Research analyses that the bispecific antibody therapeutics market was valued at USD 523.98 million in 2021 and is expected to reach USD 900.29 million by 2029, registering a CAGR of 7.0% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

In a single molecule, bispecific antibodies have two antigen-binding sites. Bispecific antibodies appear in a variety of sizes and shapes, ranging from tiny proteins with two associated antigen-binding fragments to massive IgG-like molecules with additional domains. The therapeutic success of currently existing bispecific antibodies has accelerated bispecific antibody development in oncology. According to Globaldata's database, 106 bispecific antibody compounds are in development. 45 of the 106 bispecific antibody medicines in clinical development are aimed mostly at blood cancers, while the rest are aimed at solid tumors, mostly lung and gastrointestinal cancers.

Download Exclusive Sample Report (Including Graphs, Charts & Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bispecific-antibody-therapeutics-market

Global Bispecific Antibody Therapeutics Market Scope

The bispecific antibody therapeutics market is segmented on the basis of indication, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

Oncology

Autoimmune Disease

Others

Drugs

Blinatumomab

Catumaxomab

Duligotumab

Others

Route of Administration

Intravenous

Subcutaneous

Others

End-Users

Hospitals

Specialty Clinics

Homecare

Others

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

Competitive Landscape and Bispecific Antibody Therapeutics Market Share Analysis

The bispecific antibody therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bispecific antibody therapeutics market.

Some of the major players operating in the bispecific antibody therapeutics market are:

Pfizer Inc. (U.S.)

GlaxoSmithKline plc (U.K.)

Novartis AG (Switzerland)

Sanofi (France)

AstraZeneca (U.K.)

F. Hoffmann-La Roche Ltd. (Switzerland)

Eli Lilly and Company (U.S.)

Allergan (Ireland)

Innovent Biologics, Inc. (China)

Adimab (U.S.)

Affimed GmbH (Germany)

Xencor (U.S.)

Pieris Pharmaceuticals, Inc. (U.S.)

Mereo BioPharma Group plc (U.K.)

Sobi (Sweden)

TG Therapeutics, Inc (U.S.)

Merus (Netherlands)

MacroGenics, Inc (U.S.)

Genmab A/S (Denmark)

Emergent BioSolutions Inc (U.S.)

Alteogen (South Korea)

Astellas Pharma Inc. (Japan)

Top Trendings Reports:-

https://dbmr006.blogspot.com/2023/08/plasmapheresis-periprocedural-care.html

https://dbmr006.blogspot.com/2023/08/veterinary-automatic-osmometer-market.html

https://dbmr006.blogspot.com/2023/08/aminophylline-market-is-estimated-to.html

https://dbmr006.blogspot.com/2023/08/dandy-walker-treatment-market-is-valued.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on

Contact us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Corporatesales@databridgemarketresearch.com

This release was published on openPR.